CD33 is a member of sialic acid-binding immunoglobulin-like lectins (Siglecs) expressed on early myeloid progenitors and in over 90% of AML blasts [77]; its high expression has been associated with poor clinical outcome [78]. This evidence concerns the gene CD33 and acute myeloid leukemia.